CAJ | 학술논문

目的：观察卡培他滨联合放疗在乳腺癌脑转移患者治疗中的疗效和毒副反应。资料和方法：收集青岛大学医学院附属二院肿瘤科和和四零四医院肿瘤中心2008.6-2010.4收治的32例乳腺癌脑转移患者，14例经卡培他滨联合放疗治疗，18例经其他化疗药物联合放疗治疗，回顾性比较两组近期疗效、中位生存期和毒副反应。结果：中位随访9个月，放疗联合卡培他滨组有效率（64%）和中位生存期（10.86月），与联合其他化疗组无明显差异（p>0.05）。卡培他滨组消化道反应及骨髓抑制轻于其他药物联合化疗组（p<0.05），平均住院时间明显缩短。结论：卡培他滨联合放疗治疗乳腺癌脑转移具有较好的疗效，不良反应较其他联合化疗方案轻。
목적：관찰잡배타빈연합방료재유선암뇌전이환자치료중적료효화독부반응。자료화방법：수집청도대학의학원부속이원종류과화화사령사의원종류중심2008.6-2010.4수치적32례유선암뇌전이환자，14례경잡배타빈연합방료치료，18례경기타화료약물연합방료치료，회고성비교량조근기료효、중위생존기화독부반응。결과：중위수방9개월，방료연합잡배타빈조유효솔（64%）화중위생존기（10.86월），여연합기타화료조무명현차이（p>0.05）。잡배타빈조소화도반응급골수억제경우기타약물연합화료조（p<0.05），평균주원시간명현축단。결론：잡배타빈연합방료치료유선암뇌전이구유교호적료효，불량반응교기타연합화료방안경。
Background:To observe the efficacy and safety of capecitabine and Radiation on Brest cancer transferred to brain. Patients and Methods:thirty-two cases with the above disease were collected. 14 of them treated with capecitabine and Radiation. The response rates, Median overall survival(OS), and side effects were analyzed. Results:The two groups have similar Overall response rate(ORR 64%vs. 61%) and Median overall survival(10.86 months vs. 11.67 months)(p<0.05).The side effects of those had capecitabine and Radiation was Significantly lower than others(P<0.05), and the capecitabine and Radiation group had less time in hospital.Conclusions:Capecitabine and Radiation is a feasible and effective treatment for Brest cancer transferred to brain. And side effects were Significantly lower than Other chemotherapy drugs.